Health Canada approves Aastrom's clinical trial application for heart failure drug Pharmaceutical Business Review Currently patients are being enrolled in the US to participate in the ixCELL-DCM trial, which is a randomized, double-blind, placebo-controlled study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM), ... Aastrom (ASTM) Approved Trial Application for P2b Study in Canada |
